BMY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BMY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
For the three months ended in Mar. 2024, Bristol-Myers Squibb Co's Net Income From Continuing Operations was $-11,908 Mil. Its Depreciation, Depletion and Amortization was $2,532 Mil. Its Change In Working Capital was $198 Mil. Its cash flow from deferred tax was $-711 Mil. Its Cash from Discontinued Operating Activities was $0 Mil. Its Asset Impairment Charge was $1 Mil. Its Stock Based Compensation was $133 Mil. And its Cash Flow from Others was $12,589 Mil. In all, Bristol-Myers Squibb Co's Cash Flow from Operations for the three months ended in Mar. 2024 was $2,834 Mil.
The historical data trend for Bristol-Myers Squibb Co's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Flow from Operations | Get a 7-Day Free Trial | 8,210.00 | 14,052.00 | 16,207.00 | 13,066.00 | 13,860.00 |
Bristol-Myers Squibb Co Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Flow from Operations | Get a 7-Day Free Trial | 2,970.00 | 1,887.00 | 4,751.00 | 4,252.00 | 2,834.00 |
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Bristol-Myers Squibb Co's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Operations | (A: Dec. 2023 ) | ||||||
= | Net Income From Continuing Operations | + | Depreciation, Depletion and Amortization | + | Change In Working Capital | + | Deferred Tax |
= | 8040 | + | 9760 | + | -1914 | + | -3288 |
+ | Cash from Discontinued Operating Activities | + | Asset Impairment Charge | + | Stock Based Compensation | + | Cash Flow from Others |
+ | 0 | + | 255 | + | 518 | + | 489 |
= | 13,860 |
Bristol-Myers Squibb Co's Cash Flow from Operations for the quarter that ended in Mar. 2024 is:
Cash Flow from Operations | (Q: Mar. 2024 ) | ||||||
= | Net Income From Continuing Operations | + | Depreciation, Depletion and Amortization | + | Change In Working Capital | + | Deferred Tax |
= | -11908 | + | 2532 | + | 198 | + | -711 |
+ | Cash from Discontinued Operating Activities | + | Asset Impairment Charge | + | Stock Based Compensation | + | Cash Flow from Others |
+ | 0 | + | 1 | + | 133 | + | 12589 |
= | 2,834 |
Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $13,724 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (NYSE:BMY) Cash Flow from Operations Explanation
For companies reported in indirect method, cash flow from operations contains six items:
1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Bristol-Myers Squibb Co's net income from continuing operations for the three months ended in Mar. 2024 was $-11,908 Mil.
2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets
Bristol-Myers Squibb Co's depreciation, depletion and amortization for the three months ended in Mar. 2024 was $2,532 Mil.
3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.
Bristol-Myers Squibb Co's change in working capital for the three months ended in Mar. 2024 was $198 Mil. It means Bristol-Myers Squibb Co's working capital increased by $198 Mil from Dec. 2023 to Mar. 2024 .
4. Deferred Tax:
It is the cash flow generated from deferred tax.
Bristol-Myers Squibb Co's cash flow from deferred tax for the three months ended in Mar. 2024 was $-711 Mil.
5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.
Bristol-Myers Squibb Co's cash from discontinued operating Activities for the three months ended in Mar. 2024 was $0 Mil.
6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.
Bristol-Myers Squibb Co's asset impairment charge for the three months ended in Mar. 2024 was $1 Mil.
7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.
Bristol-Myers Squibb Co's stock based compensation for the three months ended in Mar. 2024 was $133 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).
Bristol-Myers Squibb Co's cash flow from others for the three months ended in Mar. 2024 was $12,589 Mil.
Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher S. Boerner | officer: EVP, Chief Commercial Officer | 21823 30TH DRIVE S, BOTHELL WA 98021 |
Samuels Theodore R. Ii | director | 1990 E. GRAND AVE., EL SEGUNDO CA 90245 |
Cari Gallman | officer: EVP, Corporate Affairs | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Ann Powell Judge | officer: SVP, Human Resources | BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543 |
Robert M Plenge | officer: EVP, Chief Research Officer | C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Rupert Vessey | officer: Pres., Research & Early Dev. | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Adam Lenkowsky | officer: EVP, Chief Commercial Officer | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Giovanni Caforio | officer: EVP & Chief Commercial Officer | BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543 |
David V Elkins | officer: EVP, Chief Financial Officer | C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417 |
Deepak Bhatt | director | BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016 |
Sandra Leung | officer: Vice President and Secretary | C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164 |
Sharon Greenlees | officer: SVP & Controller | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Karin Shanahan | officer: EVP, Glob. Prod. Dev. & Supply | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Gregory Scott Meyers | officer: EVP, Chief Digital & Tech Off. | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Autenried Paul Von | officer: SVP, Enterp. Services & CIO | BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543 |
From GuruFocus
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.